Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial - Summary - MDSpire

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

  • By

  • Elena Murr

  • Sabine Grill

  • Marion Kiechle

  • Anne Kraemer

  • Bernadine Madl

  • Simon Glowka

  • Bernhard Haller

  • Caterina Fiorentini

  • Emmanuel Adjej

  • Mark J Haykowsky

  • Martin Halle

  • Simon Wernhart

  • June 5, 2026

  • 0 min

Share

Objective:

To evaluate the effect of a video-based, supervised, combined exercise training on VO2peak and other health outcomes in triple negative breast cancer (TNBC) patients undergoing neoadjuvant immunochemotherapy.

Key Findings:
  • The primary outcome is the change in VO2peak from baseline to 24 weeks.
  • Secondary outcomes include physical function, cardiac biomarkers, echocardiographic variables, quality of life, strength, balance, and exploratory cardiac adverse events (e.g., heart failure, arrhythmias) through 52 weeks.
Interpretation:

This study aims to significantly contribute to understanding the effects of exercise intervention during immunochemotherapy in TNBC patients.

Limitations:
  • The study is limited to patients able to participate in online training sessions with a digital device, which may introduce selection bias.
Conclusion:

The ExACT-ICI trial will provide insights into the role of exercise during neoadjuvant immunochemotherapy for TNBC, potentially informing future cardio-oncological exercise guidelines.

Original Source(s)

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

  • by Elena Murr, Sabine Grill, Marion Kiechle, Anne Kraemer, Bernadine Madl, Simon Glowka, Bernhard Haller, Caterina Fiorentini, Emmanuel Adjej, Mark J Haykowsky, Martin Halle, Simon Wernhart

  • June 5, 2026

Related Content

Integrating In silico perturbation with multilayer omics to decode regulatory networks in cancer immunity: a new frontier in precision oncology

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study

Beyond prediction: AI as a mechanistic microscope and digital twin for colorectal cancer immunotherapy